Myelo Therapeutics GmbH - Myelo001
myelo001 is a small molecule that is effective on the hematogenesis.
Its oral application is being investigated as a treatment for chemotherapy-induced neutropenia(CIN) and chemotherapy-induced thrombocytopenia (CIT).

myelo001 was found to induce the differentiation of immature myeloid precursors. The effect of myelo001 is determined by both the protection of immature granulocytic cells in their early stage after cytostatic treatment and more active maturation of neutrophils.

myelo001 has reached clinical stage in Europe with the Efficacy and Safety Phase IIa Study in Chemotherapy-Induced Neutropenia (MyeloConcept). Results are expected in the first half of 2018.